Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares Repurchased
Ratios

Corcept Therapeutics (CORT) Accumulated Depreciation & Amortization (2016 - 2023)

Corcept Therapeutics' Accumulated Depreciation & Amortization history spans 8 years, with the latest figure at $358000.0 for Q2 2023.

  • For Q2 2023, Accumulated Depreciation & Amortization fell 11.39% year-over-year to $358000.0; the TTM value through Jun 2023 reached $358000.0, down 11.39%, while the annual FY2022 figure was $3.7 million, 26.74% up from the prior year.
  • Accumulated Depreciation & Amortization for Q2 2023 was $358000.0 at Corcept Therapeutics, up from $172000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $3.7 million in Q4 2022 and bottomed at $172000.0 in Q1 2023.
  • The 5-year median for Accumulated Depreciation & Amortization is $447000.0 (2020), against an average of $1.0 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization soared 582.6% in 2021 before it plummeted 83.65% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $703000.0 in 2019, then surged by 163.58% to $1.9 million in 2020, then skyrocketed by 57.85% to $2.9 million in 2021, then grew by 26.74% to $3.7 million in 2022, then crashed by 90.34% to $358000.0 in 2023.
  • Per Business Quant, the three most recent readings for CORT's Accumulated Depreciation & Amortization are $358000.0 (Q2 2023), $172000.0 (Q1 2023), and $3.7 million (Q4 2022).